NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients
| Autor: | Pallarès, Victor, Hoyos Colell, Montserrat, Chillón, M. Carmen, Barragán, Eva, Conde, M. Isabel Prieto, Llop, Marta, Céspedes, María Virtudes, Nomdedeu, Josep, Brunet, Salut, Sanz, Miguel Ángel, González-Díaz, Marcos, Sierra, Jorge, Casanova Rigat, Isolda, Mangues, Ramon, Universitat Autònoma de Barcelona |
|---|---|
| Přispěvatelé: | Josep Carreras Leukemia Foundation, Generalitat de Catalunya, Fundació La Marató de TV3, Fundació Privada Cellex, Instituto de Salud Carlos III, European Commission, Asociación Española Contra el Cáncer |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Gerontology medicine.medical_specialty Prognostic factor acute myeloid leukemia 03 medical and health sciences 0302 clinical medicine nedd9 Internal medicine hemic and lymphatic diseases medicine bcar1 Cumulative incidence prognostic factor Gynecology intermediate-risk Hematology business.industry Myeloid leukemia University hospital medicine.disease Leukemia 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cohort business Intermediate risk Research Paper |
| Zdroj: | Oncotarget r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Digital.CSIC. Repositorio Institucional del CSIC r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| ISSN: | 1949-2553 |
| Popis: | Intermediate-risk acute myeloid leukemia (IR-AML) is the largest subgroup of AML patients and is highly heterogeneous. Whereas adverse and favourable risk patients have well-established treatment protocols, IR-AML patients have not. It is, therefore, crucial to find novel factors that stratify this subgroup to implement risk-adapted strategies. The CAS (Crk-associated substrate) adaptor protein family regulates cell proliferation, survival, migration and adhesion. Despite its association with metastatic dissemination and prognosis of different solid tumors, the role of these proteins in hematological malignancies has been scarcely evaluated. Nevertheless, previous work has established an important role for the CAS family members NEDD9 or BCAR1 in the migratory and dissemination capacities of myeloid cells. On this basis, we hypothesized that NEDD9 or BCAR1 expression levels could associate with survival in IR-AML patients and become new prognostic markers. To that purpose, we assessed BCAR1 and NEDD9 gene expression in a cohort of 73 adult AML patients validating the results in an independent cohort (n = 206). We have identified NEDD9, but not BCAR1, as a new a marker for longer overall and disease-free survival, and for lower cumulative incidence of relapse. In summary, NEDD9 gene expression is an independent prognostic factor for favourable prognosis in IR-AML patients. This work was supported by Instituto de Salud Carlos III (Co-funding from FEDER) [CD13/00074 to V.P., PI15/00378 to R.M., FIS PI11/00872, RD12/0036/0071 and FIS PI14/00450 to J.S., PIE15/00028 to R.M. and J.S., RD12/0036/0069 to M.G.D., ISCIII-PS13/1640 and RD12/0036/0014 to M.A.S.]; CIBER-BBN [CBV6/01/1031 and Nanomets3 to R.M.]; Generalitat de Catalunya [PERIS SLT002/16/00433 to J.S.]; AGAUR [2014-SGR-1041, 2014PROD0005 to R.M. and 2014-SGR-1281 to J.S.]; Fundació La Marató TV3 [416/C/2013-2030 to R.M., 100830/31/32 to J.S., M.G.D. and M.A.S.]; Josep Carreras Leukemia Research Institute [P/AG 2014 to R.M.]; Spanish Health Research Program [PI12/02321 to M.G.D.]; Spanish Association Against Cancer (AECC) [to MCC]; and a grant from the Cellex Foundation, Barcelona [to J.S.]. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|